U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C24H23NO
Molecular Weight 341.4455
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JWH-018

SMILES

CCCCCN1C=C(C(=O)C2=CC=CC3=CC=CC=C23)C4=C1C=CC=C4

InChI

InChIKey=JDNLPKCAXICMBW-UHFFFAOYSA-N
InChI=1S/C24H23NO/c1-2-3-8-16-25-17-22(20-13-6-7-15-23(20)25)24(26)21-14-9-11-18-10-4-5-12-19(18)21/h4-7,9-15,17H,2-3,8,16H2,1H3

HIDE SMILES / InChI

Description

JWH-018 is a full agonist synthetic cannabinoid with a high binding affinity to CB1 and CB2 cannabinoid receptors. JWH-018 has not been used in therapy. Many of the risks linked to cannabis use are also present in the case of JWH-018, among them complications in patients suffering from cardiovascular diseases and triggering of acute psychosis. JWH-018 has not been used in therapy. Studies in mice showed anti-inflammatory and cancer chemopreventive properties of JWH-018.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
9.0 nM [Ki]
2.94 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Preventing
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
2 to 5 mg when smoked/vaporized
Route of Administration: Other
In Vitro Use Guide
JWH-018 induces inhibition of forskolin-stimulated cAMP accumulation in CHO cell lines expressing CB1 receptors with an EC50 14.7 ± 3.9, maximum inhibition 79% and in Neuro2AWT cells with an EC50 of 5.31 ± 0.4 nM.